Topic: multiple sclerosis
Last July, Roche put a halt on U.S. price hikes. But that didn't stop five of its products from topping analysts' estimates by double digits in Q1.
After a tough year in the competitive MS field, Sanofi’s Lemtrada could hardly afford another setback. But that’s exactly what it got.
Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.
Rejected in 2011, Mavenclad won FDA approval with a label that's not ideal—but that doesn't necessarily hurt its blockbuster odds, says one analyst.
Novartis officially has approval for Mayzent to treat patients with secondary progressive multiple sclerosis.
Roche grew sales by 7% in 2018, even as biosimilar rivals unleashed damage in Europe. But 2019 will be the moment of truth for the Swiss drugmaker. U.S. copycats to its trio of cancer megablockbusters—Herceptin, Rituxan and Avastin—are expected to arrive.
Credit Suisse analysts have uncovered a Novartis patent that they fear could be a threat to ozanimod, Celgene's phase 3 multiple sclerosis candidate.
Teva's Copaxone is losing ground to generic competition—and the company's newer drugs aren’t taking off fast enough to make up for the loss.
After a strong fourth quarter, Sanofi expects further growth in 2019.
Roche expects 2019 sales growth in low- to mid-single digits, compared with 7% in 2018, partially on expected U.S. biosimilar launches.